Aditya,MDBardiaMD

Oncology • Santa Monica, CA

Physician

Join to view full profile

Dr. Bardia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bardia's full profile

Already have an account?

Office
2336 Santa Monica Blvd
Ste 304
Santa Monica, CA 90404
Phone+1 310-998-4747

Education & Training

All India Institute of Medical SciencesClass of 2003

Certifications & Licensure

CA State Medical License 2024 - 2026
MA State Medical License 2011 - 2025
MD State Medical License 2008 - 2012
MN State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Start of enrollment: 2017 Dec 12
Recruiting
Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Brea...
Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis
Journal of Clinical Oncology. 2024-09-12

Press Mentions

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients with HR-Positive, HER2-Negative Breast Cancer Primary Results from TROPION-Breast01October 29th, 2024
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22nd, 2024
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22nd, 2024
Join now to see all